Nicolas Cuburu

Dr. Nicolas Cuburu

Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Nicolas CuburuNicolas Cuburu
Nicolas Cuburu
SKSelina Khan
Selina Khan
CTCynthia D. Thompson
Cynthia D. Thompson
RKRina Kim
Rina Kim
JVJort Vellinga
Jort Vellinga
JSJohn T. Schiller
John T. Schiller

15 February 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Nicolas CuburuNicolas Cuburu
Nicolas Cuburu
RKRina Kim
Rina Kim
GGGeoffrey C. Guittard
Geoffrey C. Guittard
CTCynthia D. Thompson
Cynthia D. Thompson
PDPatricia Day
Patricia Day
JSJohn T Schiller
John T Schiller
Recent insight into the mechanisms of induction of tissue-resident memory (TRM) CD8+ T cells (CD8+ TRM) enables the development of novel vaccine strategies against sexually transmitted infections. To maximize both systemic and genital intraepithelial CD8+ T cells against vaccine Ags, we assessed combinations of i.m. and intravaginal routes in heterologous prime-boost immunization regimens with unrelated viral vectors. Only i.m. prime followed by intravaginal boost induced concomitant strong systemic and intraepithelial genital-resident CD8+ T cell responses. Intravaginal boost with vectors expressing vaccine Ags was far superior to intravaginal instillation of CXCR3 chemokine receptor ligands or TLR 3, 7, and 9 agonists to recruit and increase the pool of cervicovaginal CD8+ TRM. Transient Ag presentation increased trafficking of cognate and bystander circulating activated, but not naive, CD8+ T cells into the genital tract and induced in situ proliferation and differentiation of cognate CD8+ TRM. Secondary genital CD8+ TRM were induced in the absence of CD4+ T cell help and shared a similar TCR repertoire with systemic CD8+ T cells. This prime-pull-amplify approach elicited systemic and genital CD8+ T cell responses against high-risk human papillomavirus type 16 E7 oncoprotein and conferred CD8-mediated protection to a vaccinia virus genital challenge. These results underscore the importance of the delivery route of nonreplicating vectors in prime-boost immunization to shape the tissue distribution of CD8+ T cell responses. In this context, the importance of local Ag presentation to elicit genital CD8+ TRM provides a rationale to develop novel vaccines against sexually transmitted infections and to treat human papillomavirus neoplasia.

7 July 2016 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
Nicolas CuburuNicolas Cuburu
Nicolas Cuburu
JSJohn T. Schiller
John T. Schiller
Persistent human papillomavirus (HPV) is the primary etiologic agent of cervical cancer and causes a significant number of vulvar, penile, anal and oropharyngeal cancers. The development of highly effective HPV therapeutic vaccines is a reasonable goal given the recent advances in basic and applied immunology. A number of vaccine strategies designed to induce systemic T cell responses have been tested in clinical trials against high grade cervical or vulvar high grade neoplasia and cancers, but with limited success. In line with the emerging trend to focus more on the epithelial context of HPV infection and premalignant disease, it might be advantageous to develop vaccination strategies that promote trafficking of HPV-specific T cells into lesions and overcome the local immunosuppressive environment. The development of more biologically relevant animal models would improve the preclinical evaluation of therapeutic vaccine candidates. Finally, persistent infection and low grade lesions may prove to be easier targets for therapeutic vaccines, and these vaccines would likely be commercially viable in high income countries and valuable components in screen and treat programs in low resource settings.

3 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CTCharles Torgbor
Charles Torgbor
HSHaewon Sohn
Haewon Sohn
BDBrian L. P. Dizon
Brian L. P. Dizon
EMEvan C. Mutic
Evan C. Mutic
RGRachel George
Rachel George
SPSusan K. Pierce
Susan K. Pierce
B cell responses to membrane-presented antigens appear to be strongly favored over soluble antigens in vivo suggesting that vaccines that mimic membrane-presented antigens may be highly efficacious. We recently demonstrated that human B cell responses to membrane-associated but not to soluble antigens in vitro depended on the expression and activity of the plasma membrane mechanosensitive ion channel, Piezo1. Here, we provide evidence that the efficacy of the current human papillomavirus virus-like particle (HPV VLP) vaccines may be due in part to their inherent ability to mimic Piezo1-dependent membrane presentation of antigens to B cells. We compared HPV-specific human B cell responses to HPV VLPs versus soluble HPV pentameric capsomeres and showed that although both induced calcium responses, only HPV VLP-induced responses were blocked by Piezo1 inhibitors. The kinetics of internalization of HPV-VLP and capsomeres into HPV-specific B cells were similar and neither required Piezo1 function as shown by small interfering RNA (siRNA)-mediated knockdown of Piezo. However, trafficking of HPV-VLPs into intracellular major histocompatibility complex (MHC) class II, lysosomal associated membrane protein 1 (LAMP1) + antigen-processing compartments was Piezo1-dependent, whereas trafficking of capsomeres was not. In addition, a time course of intracellular trafficking suggested that colocalization of HPV-VLP with MHC classII was more stable over time as compared to capsomeres. Taken together these findings suggest that the ability of HPV-VLP vaccines to mimic Piezo1-dependent membrane antigen presentation may be exploited in the design of highly effective human vaccines.

25 April 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
SSShiv K. Sethi
Shiv K. Sethi
CBClaire E. Bradley
Claire E. Bradley
LBLukas Bialkowski
Lukas Bialkowski
YPYuk Ying Pang
Yuk Ying Pang
CTCynthia D. Thompson
Cynthia D. Thompson
Nicolas CuburuNicolas Cuburu
Nicolas Cuburu
Intratumoral (IT) immunotherapy can stimulate the tumor microenvironment and enhance anti-tumor immunity. We investigated IT delivery of three licensed viral vaccines—Shingrix (VZV shingles), Gardasil-9 (HPV), and Spikevax (SARS-CoV-2)—in prevaccinated mice using the murine tumor model TC-1, which expresses HPV16 oncogenes E6 and E7. Shingrix IT injection often induced tumor regression and resistance to secondary challenge. Injecting a VZV glycoprotein E (gE)-derived MHC-II-restricted peptide with polyI:C also led to durable remission, highlighting the role of gE-specific CD4+ T cells. While Gardasil-9 IT injection alone was ineffective, combining a HPV L1-derived MHC-I-restricted peptide with polyI:C or Shingrix enhanced tumor regression. Both approaches elicited CD8+ T cells against the E7 tumor viral oncoprotein. Tumor microenvironment analysis revealed remodeling of the myeloid compartment, significant induction of IFN-γ, TNF-α, and CXCL9 and broad gene expression reprograming. In a dual-flank model, IT injection of Shingrix with an MHC-I-restricted E7 tumor-specific peptide eliminated primary and non-injected tumors. Finally, Spikevax IT injection showed modest tumor growth delay, while improved control was observed with a SARS-CoV-2 spike-derived MHC-I-restricted peptide and polyI:C. These results demonstrate the potential of licensed vaccines as promising platforms for IT immunotherapy, either alone or combined with vaccine- or tumor-derived MHC-I-restricted peptide epitopes.

1 September 2011 in Expert Review of Vaccines
Verified
Journal Article
Open access
Nicolas CuburuNicolas Cuburu
Nicolas Cuburu
BCBryce Chackerian
Bryce Chackerian
Sexually transmitted diseases represent a significant cause of mortality and morbidity worldwide. The genital mucosa is the first line of defense against sexually transmitted pathogens and, like other mucosal tissues, it is colonized by resident immune cells that initiate an immune responses that can prevent the establishment and dissemination of infection. While it is clear that systemic vaccination is sufficient to provide protection against certain pathogens that infect the genital tract, such as human papillomavirus (HPV) and hepatitis B virus (HBV), it has not worked for other. Induction of local mucosal immune responses in the genital tract might increase the efficacy of vaccines targeting HSV, HIV and other sexually transmitted infections. Here, we describe recent promising efforts to induce adaptive immune responses in the genital tract using vaccines based on virus-like particles (VLPs) and pseudoviruses (PsVs).